LGALS9 and neoplasm: Immune checkpoints expressed in tumor cells, including PD-L1 (CD274), galectin 9 (LGALS9), HVEM (TNFRSF14), exhaust CD8+ T cells and reduce CD8+ T-derived cytotoxicity [13,14,15].